(FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | (Q3)Mar 31, 2022 | (FY)Dec 31, 2021 | (Q9)Sep 30, 2021 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 166.74%141.1B | 150.61%105.48B | 148.88%59.61B | 94.06%25.07B | -29.03%52.9B | -26.75%42.09B | -36.40%23.95B | -11.41%12.92B | 7.23%74.53B | 18.58%57.46B |
Operating income | 166.74%141.1B | 150.61%105.48B | 148.88%59.61B | 94.06%25.07B | -29.03%52.9B | -26.75%42.09B | -36.40%23.95B | -11.41%12.92B | 7.23%74.53B | 18.58%57.46B |
Operating expenses | -58.54%-97.36B | -33.68%-26.32B | 2.75%-61.41B | -2.32%-19.69B | -19.27%-63.15B | |||||
Gross profit | 142.01%8.12B | 81.51%-1.25B | -239.44%-19.32B | -45.28%-6.77B | -26.73%-5.69B | |||||
Selling expenses | -108.76%-3.42B | -47.31%-4B | -69.74%-1.54B | -6.85%-1.12B | 36.35%-1.64B | 18.20%-2.71B | 20.31%-908.62M | 4.34%-1.05B | -0.31%-2.58B | -11.75%-3.32B |
Administrative expenses | -35.71%-1.68B | -15.41%-3.73B | -39.03%-706.17M | -4.16%-1.11B | 1.80%-1.24B | 0.39%-3.23B | -8.19%-507.94M | -0.93%-1.07B | -20.12%-1.26B | -18.53%-3.24B |
Research and development expenses | ---- | -69.45%-213.84M | ---- | -82.88%-69.68M | ---- | -35.97%-126.2M | ---- | -25.95%-38.1M | ---- | 58.45%-92.81M |
Profit from asset sales | ---- | 21,814.86%689.66M | ---- | 2,025.82%25.36M | ---- | -112.31%-3.18M | ---- | 230.53%1.19M | ---- | -11.29%25.8M |
Employee expense | -15.64%-29.3B | ---- | -18.79%-13.59B | ---- | -4.57%-25.34B | ---- | -1.26%-11.44B | ---- | -10.07%-24.23B | ---- |
Depreciation and amortization | -27.68%-27.11B | ---- | -21.48%-12.7B | ---- | -1.43%-21.23B | ---- | -1.23%-10.46B | ---- | -2.58%-20.93B | ---- |
Revaluation surplus | ---- | -13.94%-711K | ---- | 58.75%-271K | ---- | ---624K | ---- | ---657K | ---- | ---- |
-Changes in the fair value of other assets | ---- | -13.94%-711K | ---- | 58.75%-271K | ---- | ---624K | ---- | ---657K | ---- | ---- |
Impairment and provision | -406.39%-211.67M | -56,672.02%-123.76M | -745.47%-102.67M | -189.37%-4.42M | 67.89%-41.8M | -100.23%-218K | 270.94%15.91M | 194.64%4.95M | 62.50%-130.16M | 36.84%95.82M |
-Impairment of intangible assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---750K | ---- |
-Impairment of property, machinery and equipment | ---- | ---- | ---91.16M | ---- | ---- | ---- | ---- | ---- | 33.46%-292.56M | ---- |
-Other impairment is provision | -406.39%-211.67M | -56,672.02%-123.76M | -172.35%-11.51M | -189.37%-4.42M | -125.62%-41.8M | -100.23%-218K | 270.94%15.91M | 194.64%4.95M | 76.19%163.15M | 36.84%95.82M |
Special items of operating profit | -96.88%-76.48B | 260.58%5.45B | -80.80%-31.86B | 696.90%1.37B | 8.08%-38.85B | 13.89%1.51B | 13.84%-17.62B | -70.69%-228.85M | -23.26%-42.26B | 296.04%1.33B |
Operating profit | 108.15%2.89B | 124.74%5.93B | 94.71%-898.2M | 75.70%-2.24B | -110.20%-35.44B | -116.33%-23.98B | -180.88%-16.97B | -30.63%-9.2B | -50.98%-16.86B | 0.58%-11.09B |
Financing income | 164.52%605M | ---- | 215.49%291.38M | ---- | 104.10%228.72M | ---- | 124.09%92.36M | ---- | -41.51%112.06M | ---- |
Financing cost | -7.27%-6.94B | 32.05%-6.36B | -12.76%-3.54B | 15.34%-1.06B | -17.79%-6.47B | -160.63%-9.36B | -18.17%-3.14B | 22.57%-1.25B | -7.75%-5.5B | -46.96%-3.59B |
Share of profits of associates | 635.05%2.55B | ---- | 221.53%1.27B | ---- | 56.15%-477.41M | ---- | 26.61%-1.04B | ---- | 82.29%-1.09B | ---- |
Share of profit from joint venture company | -25.82%279.57M | ---- | -60.85%88.82M | ---- | 38.07%376.87M | ---- | 105.74%226.89M | ---- | 75.49%272.97M | ---- |
Special items of earning before tax | 74.68%-1.04B | 8,257.19%1.37B | 30.11%-1.57B | 35.04%12.51M | -430.95%-4.09B | -150.85%-16.81M | -497.48%-2.24B | -53.87%9.27M | -65.72%1.24B | 28.27%33.06M |
Earning before tax | 96.40%-1.65B | 102.82%941.12M | 81.11%-4.36B | 68.56%-3.28B | -110.20%-45.88B | -127.80%-33.36B | -145.36%-23.08B | -20.88%-10.44B | -18.19%-21.83B | -7.93%-14.65B |
Tax | -87.41%88.53M | -74.14%245.72M | -63.30%316.22M | -98.46%8.79M | -76.59%702.98M | -66.65%950.07M | -50.32%861.65M | -66.32%569.55M | 13.32%3B | 35.21%2.85B |
After-tax profit from continuing operations | 96.54%-1.56B | 103.66%1.19B | 81.80%-4.04B | 66.84%-3.27B | -140.00%-45.17B | -174.76%-32.41B | -189.60%-22.21B | -42.10%-9.87B | -19.01%-18.82B | -2.92%-11.8B |
Earning after tax | 96.54%-1.56B | 103.66%1.19B | 81.80%-4.04B | 66.84%-3.27B | -140.00%-45.17B | -174.76%-32.41B | -189.60%-22.21B | -42.10%-9.87B | -19.01%-18.82B | -2.92%-11.8B |
Minority profit | 92.03%-522.84M | 109.18%395.42M | 78.50%-597.14M | 64.27%-347.24M | -199.78%-6.56B | -192.19%-4.31B | -212.32%-2.78B | -31.45%-971.74M | -54.80%-2.19B | -9.24%-1.47B |
Profit attributable to shareholders | 97.31%-1.04B | 102.82%791.42M | 82.27%-3.45B | 67.12%-2.93B | -132.14%-38.62B | -172.27%-28.1B | -186.62%-19.44B | -43.37%-8.9B | -15.50%-16.64B | -2.07%-10.32B |
Basic earnings per share | 97.60%-0.0674 | 102.44%0.05 | 84.18%-0.2239 | 70.77%-0.19 | -132.13%-2.8116 | -173.33%-2.05 | -186.63%-1.4151 | -44.44%-0.65 | -15.50%-1.2112 | -1.35%-0.75 |
Diluted earnings per share | 97.60%-0.0674 | 84.18%-0.2239 | -132.13%-2.8116 | -186.63%-1.4151 | -15.50%-1.2112 | |||||
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) |
Audit Opinions | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- |
Auditor | Deloitte & Touche Tohmatsu, Deloitte Touche Tohmatsu (Special General Partnership) | -- | -- | -- | Deloitte & Touche Tohmatsu, Deloitte Touche Tohmatsu (Special General Partnership) | -- | -- | -- | Deloitte & Touche Tohmatsu, Deloitte Touche Tohmatsu (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data
No Data